除了糖尿病之外的SGLT-2抑制剂:癌症治疗的新前沿
Ali Nakhaei1, Kiana Delavar1, Azin Sadat Azim1
1Student Research Committee, MMS.C., Islamic Azad University, Mashhad, Iran.
Diabetes research and clinical practice
|September 28, 2025
概括
用于糖尿病的-葡萄糖共运输体2 (SGLT-2) 抑制剂,作为抗癌药物表现有前途. 这些药物抑制了癌细胞中葡萄糖的吸收,通过各种细胞途径表现出广泛的抗增殖作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- -葡萄糖共运输体2 (SGLT-2) 存在于各种癌症细胞系中.
- 癌细胞经常表现出增加的葡萄糖依赖性扩散.
- SGLT-2 抑制剂是已知的抗糖尿病药物,具有已知的安全性.
研究的目的:
- 为了探索SGLT-2抑制剂的抗癌潜力.
- 调查SGLT-2抑制剂抗癌作用背后的机制.
- 评估SGLT-2抑制剂作为瘤学新型治疗剂.
主要方法:
- 在多种癌症类型中进行了体外和体内研究.
- 评估了SGLT-2抑制剂的抗增殖作用.
- 分析了受SGLT-2抑制剂影响的细胞内和细胞外信号通路.
主要成果:
- 在各种癌症模型中,SGLT-2 抑制剂显示出显著的抗增殖作用.
- 这些效应是通过独立于SGLT-2活动的机制观察到的.
- 调节的关键途径包括涉及微RNA,AMPK,ERK,DNA/RNA代谢,ATP稳态和线粒体功能.
结论:
- SGLT-2 抑制剂代表了癌症治疗的有前途的治疗策略.
- 它们的抗癌疗效是由多种信号通路介导的,因此具有广泛的适用性.
- 需要在瘤学领域进行进一步的临床研究,以利用这些发现.
关键词:
在Canagliflozin中使用.癌症 癌症 癌症 癌症达帕格利弗洛辛 (Dapagliflozin) 是一种恩帕格利弗洛辛 (Empagliflozin) 是一种非常重要的药物.SGLT-2 抑制剂的使用.更多相关视频
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.1K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Secondary Active Transport
9.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.3K
Secondary Active Transport
137.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
137.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
